202 related articles for article (PubMed ID: 28181369)
21. A cost-effectiveness analysis of the prophylaxis versus on-demand regimens in severe hemophilia A patients under 12 years old in southern Iran.
Zahedi Z; Karimi M; Keshavarz K; Haghpanah S; Ravangard R
Hematology; 2021 Dec; 26(1):240-248. PubMed ID: 33594948
[TBL] [Abstract][Full Text] [Related]
22. Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia.
Thorat T; Neumann PJ; Chambers JD
J Manag Care Spec Pharm; 2018 Jul; 24(7):632-642. PubMed ID: 29952709
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of recombinant factor VIII Fc versus emicizumab for prophylaxis in adults and adolescents with haemophilia A without inhibitors in the UK.
Kragh N; Tytula A; Pochopien M; Aballéa S; Toumi M; Hakimi Z; Nazir J; Bystrická L; Fatoye F
Eur J Haematol; 2023 Mar; 110(3):262-270. PubMed ID: 36398467
[TBL] [Abstract][Full Text] [Related]
24. Prophylaxis use of clotting factor replacement products in people with non-severe haemophilia: A review of the literature.
Iorio A; Königs C; Reding MT; Rotellini D; Skinner MW; Mancuso ME; Berntorp E
Haemophilia; 2023 Jan; 29(1):33-44. PubMed ID: 36224704
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of hip protector use on a geriatric ward in Germany: a Markov model.
Stollenwerk B; Bartmus T; Klug F; Stock S; Müller D
Osteoporos Int; 2015 Apr; 26(4):1367-79. PubMed ID: 25572047
[TBL] [Abstract][Full Text] [Related]
26. Secondary prophylaxis treatment versus on-demand treatment for patients with severe haemophilia A: comparisons of cost and outcomes in Taiwan.
Liou WS; Tu TC; Cheng SN; Chou TY; Lee CF; Lin TK; Chung MI; Cham TM
Haemophilia; 2011 Jan; 17(1):45-54. PubMed ID: 20722742
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.
Polack B; Trossaërt M; Cousin M; Baffert S; Pruvot A; Godard C
Haemophilia; 2021 Jan; 27(1):e1-e11. PubMed ID: 33210412
[TBL] [Abstract][Full Text] [Related]
28. Real-world resource use and costs of haemophilia A-related bleeding.
Shrestha A; Eldar-Lissai A; Hou N; Lakdawalla DN; Batt K
Haemophilia; 2017 Jul; 23(4):e267-e275. PubMed ID: 28574162
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A.
Iannazzo S; Cortesi PA; Crea R; Steinitz K; Mantovani LG; Gringeri A
Blood Coagul Fibrinolysis; 2017 Sep; 28(6):425-430. PubMed ID: 27898515
[TBL] [Abstract][Full Text] [Related]
30. Cost-utility analysis of factor VIII diet therapies prepared using blood plasma vs. recombinant technique for patients with hemophilia A.
Lotfi F; Talebianpour H; Keshavarz K; Emadi F; Bordbar MR; Bastani P
Daru; 2020 Jun; 28(1):287-293. PubMed ID: 32323144
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness Analysis of Prophylaxis Versus On-demand Treatment for Children With Hemophilia B Without Inhibitors in China.
Liu G; Xin Q; Chen Z; Li L; Chen T; Wu R
Clin Ther; 2021 Sep; 43(9):1536-1546. PubMed ID: 34392959
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.
Abbonizio F; Giampaolo A; Coppola A; ; Arcieri R; Hassan HJ
Haemophilia; 2014 Jul; 20(4):e243-50. PubMed ID: 24834967
[TBL] [Abstract][Full Text] [Related]
34. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors.
Knight C; Paisley S; Wight J; Jones ML
Haemophilia; 2003 Jul; 9(4):521-40. PubMed ID: 12828681
[TBL] [Abstract][Full Text] [Related]
35. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Haentjens P; De Groote K; Annemans L
Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran.
Daliri AA; Haghparast H; Mamikhani J
Int J Technol Assess Health Care; 2009 Oct; 25(4):584-7. PubMed ID: 19845990
[TBL] [Abstract][Full Text] [Related]
37. [Prophylactic factor substitution in severe haemophilia A. Economic assessment in adult patients].
Berger K; Schopohl D; Eheberg D; Oldenburg J; Tiede A; Schramm W
Hamostaseologie; 2014; 34(4):291-300. PubMed ID: 25370177
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Hernandez-Pastor LJ; Ortega A; Garcia-Layana A; Giraldez J
Clin Ther; 2008 Dec; 30(12):2436-51. PubMed ID: 19167602
[TBL] [Abstract][Full Text] [Related]
39. Treatment of children with severe haemophilia A and inhibitors: a health economic evaluation for Germany.
Berger K; Schopohl D; Eheberg D; Auerswald G; Kurnik K; Schramm W
Klin Padiatr; 2013 May; 225(3):152-8. PubMed ID: 23519749
[TBL] [Abstract][Full Text] [Related]
40. Prophylactic use of factor VIII: an economic evaluation.
Bohn RL; Avorn J; Glynn RJ; Choodnovskiy I; Haschemeyer R; Aledort LM
Thromb Haemost; 1998 May; 79(5):932-7. PubMed ID: 9609224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
